Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.405
-0.145 (-9.35%)
Mar 31, 2025, 1:15 PM EDT - Market open
Allogene Therapeutics Revenue
In the year 2024, Allogene Therapeutics had annual revenue of $22.00K, down -76.84%.
Revenue (ttm)
$22.00K
Revenue Growth
-76.84%
P/S Ratio
14,270.34
Revenue / Employee
$96
Employees
229
Market Cap
305.26M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ALLO News
- 17 days ago - Allogene Therapeutics, Inc. (ALLO) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 17 days ago - Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update - GlobeNewsWire
- 4 weeks ago - Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update - GlobeNewsWire
- 4 weeks ago - Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities - Seeking Alpha
- 4 weeks ago - Allogene Therapeutics Announces Participation in March Investor Conference - GlobeNewsWire
- 4 weeks ago - Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia - GlobeNewsWire
- 4 weeks ago - Allogene Therapeutics: Disrupting CAR-T With A Scalable Model - Seeking Alpha
- 6 weeks ago - Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology - GlobeNewsWire